Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of ABBV-1042 in Healthy Subjects
NCT07222709Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABBV-1042 (6 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants Experiencing Adverse Events at 32 days, Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements at 3 days and 10 more. Started Oct 2025; status: completed.
02
Drugs
ABBV-1042
Beyond the preview
Go deeper on NCT07222709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222709.